BioStock: Dicot gets green light for start of phase I study

Dicot now takes the next big step in the development of LIB-01. The company has received approval from the Swedish Medical Products Agency to conduct its phase I study with the drug candidate. This means that the study will start as planned in August. BioStock contacted Dicot’s CEO Elin Trampe to find out more about the study.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/dicot-gets-green-light-for-start-of-phase-i-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se